Reimbursement for Vizamyl
As with all β-amyloid detection agents, Medicare will not cover the use of Vizamyl unless patients are involved in approved clinical studies such as the Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study, which is currently being conducted. Learn more about the IDEAS Study at www.ideas-study.org. For questions about Vizamyl reimbursement, please contact the GE Healthcare Reimbursement Hotline at 800 767 6664.
To enroll patients in the IDEAS Study, both dementia specialists and positron emission tomography (PET) facilities must be registered with and approved by the American College of Radiology (ACR), the sponsor of the study. For more detailed information on the IDEAS study and site eligibility requirements, please download our brochure, or contact GE Healthcare Medical Affairs at 800 654 0118 (option 2, then option 3) for more information.
For non-Medicare coverage, please contact the specific insurer to verify your benefits. Insurance policies vary and preauthorization will likely be required to establish the medical necessity for the procedure. Payment for Vizamyl and the PET scan would be based on the terms of your facility’s contractual agreement with the insurer.
2017 Coverage With Evidence Development (CED) Coding: Hospital Outpatient Coding, Freestanding Imaging Center (FSIC) Coding and Reimbursement for Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study
To check availability and order Vizamyl: Please contact your local GE Healthcare Neurology Sales Specialist, call GE Healthcare Customer Service at 800 292 8514, or email CUSTSVSNUCLEAR@GE.com.